Live Breaking News & Updates on திறமையான அல்லாத ஆக்கிரமிப்பு சோதனைகள்

ResearchAndMarkets.com’s offering.
Sales for the NASH market to grow from $144.4M in 2019 to $27.2B in 2029 at a Compound Annual Growth Rate (CAGR) of 68.8% across the 7MM.
At the end of 2029, the US will contribute around 94.3% of global sales, while the 5EU and Japan will account for around 4.5% and 1.2% of sales, respectively.
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem. However, symptoms including fatigue, weight loss, and weakness emerge once the disease has progressed to a more advanced stage, like cirrhosis. NASH is suspected if elevated liver enzymes are detected during routine blood panels, but ....

United Kingdom , Abbvie Allergan , Inventiva Pharma , Laura Wood , Novo Nordisk Ozempic , Office Hours Call , Madrigal Pharmaceuticals , Galmed Pharmaceuticals , E St Office Hours Call , Biopharmaceuticals Inc , Intercept Pharmaceuticals , Bristol Myers Squibb , Novo Nordisk , Alcoholic Steatohepatitis , Opportunity Analysis , Compound Annual Growth Rate , Topics Covered , Executive Summary , Growth Expected , Successive Drug Approvals , Approaches Will Become , Key Strategy , Unmet Need Remains Significant , Non Invasive Tests , Pipeline Products Demonstrating High Levels , Acquire Large Market Share ,